This post was originally published on this site

Vistagen Therapeutics (VTGN +4.5%) received a notification letter from Nasdaq granting 180-day extension to regain compliance with Nasdaq’s minimum bid price requirement.

The Company now time until April 12, 2021 to meet the requirement.

“We believe we will regain compliance during the extended time period as we continue to advance the three differentiated drug candidates in our CNS pipeline, a pipeline with exciting potential to go beyond the current standard of care for multiple anxiety and depression disorders, as well as several neurological conditions,” says Shawn K. Singh, CEO.